Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III-Study On All-Trans Retinoic Acid [tretinoin] in Combination With Standard Induction- And Consolidation Therapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia.

Next Previous
X
Search
Trial Profile

Phase III-Study On All-Trans Retinoic Acid [tretinoin] in Combination With Standard Induction- And Consolidation Therapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tretinoin (Primary) ; Cytarabine; Etoposide; Idarubicin; Mitoxantrone; Valproic acid
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Sep 2017 Results comparing induction therapy with consolidation therapy (n=562) presented at the 42nd European Society for Medical Oncology Congress
    • 06 Dec 2016 Results assessing minimal residual disease monitoring in Acute Myeloid Leukemia study group (AML HD93, NCT00146120, NCT00151255, NCT00151242, NCT00850382 and NCT02013648 trials) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Oct 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top